Patents by Inventor Vladimir L. Motin

Vladimir L. Motin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10076562
    Abstract: Provided herein are methods for using compositions that include a fusion protein having a YscF protein domain, a mature F1 protein domain, and a LcrV protein domain. In one embodiment the composition is used to confer immunity to plague, such as pneumonic plague, caused by Yersinia pestis. In one embodiment, the composition is administered to a mucosal surface, such as by an intranasal route. In one embodiment, the administration to a mucosal surface includes a vector that has a polynucleotide encoding a fusion protein, where the fusion protein includes a YscF protein domain, a mature F1 protein domain, and a LcrV protein domain. The administration is followed by a second administration by a different route, such as an intramuscular route. The second administration includes a fusion protein having the same three domains, and in one embodiment the fusion protein is the same one administered to a mucosal surface.
    Type: Grant
    Filed: April 18, 2017
    Date of Patent: September 18, 2018
    Assignees: The Board of Regents of the University of Texas System, Norwell, Inc.
    Inventors: Ashok K. Chopra, Vladimir L. Motin, Eric Rothe
  • Publication number: 20170296644
    Abstract: Provided herein are methods for using compositions that include a fusion protein having a YscF protein domain, a mature F1 protein domain, and a LcrV protein domain. In one embodiment the composition is used to confer immunity to plague, such as pneumonic plague, caused by Yersinia pestis. In one embodiment, the composition is administered to a mucosal surface, such as by an intranasal route. In one embodiment, the administration to a mucosal surface includes a vector that has a polynucleotide encoding a fusion protein, where the fusion protein includes a YscF protein domain, a mature F1 protein domain, and a LcrV protein domain. The administration is followed by a second administration by a different route, such as an intramuscular route. The second administration includes a fusion protein having the same three domains, and in one embodiment the fusion protein is the same one administered to a mucosal surface.
    Type: Application
    Filed: April 18, 2017
    Publication date: October 19, 2017
    Inventors: Ashok K. Chopra, Vladimir L. Motin, Eric Rothe
  • Patent number: 9187523
    Abstract: The present invention is directed to peptide sequences that were identified from combinatorial libraries and could serve as substrates of plague plasminogen activator (Pla). Another aspect of the present invention is drawn to peptides derived from the substrates for Pla as a result of chemical modifications leading to specific inactivation of the proteolytic activity of Pla. Additionally, the present invention is directed to the use of the substrates identified herein in the detection of bacteria expressing omptin family of proteases which includes Y. pestis. Furthermore, the present invention is also directed to the use of the inhibitors identified herein in the prevention and treatment of infection caused by these bacteria.
    Type: Grant
    Filed: August 29, 2011
    Date of Patent: November 17, 2015
    Assignee: The Board of Regents of the University of Texas System
    Inventors: Vladimir L. Motin, Sadhana Chauhan, Scott R. Gilbertson, Anton Agarkov, Pedro Lory
  • Publication number: 20120045474
    Abstract: The present invention is directed to peptide sequences that were identified from combinatorial libraries and could serve as substrates of plague plasminogen activator (Pla). Another aspect of the present invention is drawn to peptides derived from the substrates for Pla as a result of chemical modifications leading to specific inactivation of the proteolytic activity of Pla. Additionally, the present invention is directed to the use of the substrates identified herein in the detection of bacteria expressing omptin family of proteases which includes Y. pestis. Furthermore, the present invention is also directed to the use of the inhibitors identified herein in the prevention and treatment of infection caused by these bacteria.
    Type: Application
    Filed: August 29, 2011
    Publication date: February 23, 2012
    Inventors: Vladimir L. Motin, Sadhana Chauhan, Scott R. Gilbertson, Anton Agarkov, Pedro Lory
  • Patent number: 8030447
    Abstract: The present invention is directed to peptide sequences that were identified from combinatorial libraries and could serve as substrates of plague plasminogen activator (Pla). Another aspect of the present invention is drawn to peptides derived from the substrates for Pla as a result of chemical modifications leading to specific inactivation of the proteolytic activity of Pla. Additionally, the present invention is directed to the use of the substrates identified herein in the detection of bacteria expressing omptin family of proteases which includes Y. pestis. Furthermore, the present invention is also directed to the use of the inhibitors identified herein in the prevention and treatment of infection caused by these bacteria.
    Type: Grant
    Filed: September 20, 2007
    Date of Patent: October 4, 2011
    Assignee: The Board of Regents of the University of Texas System
    Inventors: Vladimir L. Motin, Sadhana Chauhan, Scott R. Gilbertson, Anton Agarkov, Pedro Lory
  • Publication number: 20090069248
    Abstract: The present invention is directed to peptide sequences that were identified from combinatorial libraries and could serve as substrates of plague plasminogen activator (Pla). Another aspect of the present invention is drawn to peptides derived from the substrates for Pla as a result of chemical modifications leading to specific inactivation of the proteolytic activity of Pla. Additionally, the present invention is directed to the use of the substrates identified herein in the detection of bacteria expressing omptin family of proteases which includes Y. pestis. Furthermore, the present invention is also directed to the use of the inhibitors identified herein in the prevention and treatment of infection caused by these bacteria.
    Type: Application
    Filed: September 20, 2007
    Publication date: March 12, 2009
    Inventors: Vladimir L. Motin, Sadhana Chauhan, Scott R. Gilbertson, Anton Agarkov, Pedro Lory
  • Patent number: 6964770
    Abstract: Described is a plasmid prepared by recombinant techniques which is used to prepare a vaccine against Y. pestis.
    Type: Grant
    Filed: October 27, 2003
    Date of Patent: November 15, 2005
    Assignee: Michigan State University
    Inventors: Robert R. Brubaker, Vladimir L. Motin, George B. Smirnov
  • Publication number: 20040126390
    Abstract: Described is a plasmid prepared by recombinant techniques which is used to prepare a vaccine against Y. pestis.
    Type: Application
    Filed: October 27, 2003
    Publication date: July 1, 2004
    Applicant: Michigan State University
    Inventors: Robert R. Brubaker, Vladimir L. Motin, George B. Smirnov
  • Patent number: 6638510
    Abstract: Described is a plasmid prepared by recombinant techniques which is used to prepare a vaccine against Y. pestis.
    Type: Grant
    Filed: September 8, 1994
    Date of Patent: October 28, 2003
    Assignee: Board of Trustees of Michigan State University
    Inventors: Robert R. Brubaker, Vladimir L. Motin, George B. Smirnov
  • Patent number: RE49514
    Abstract: Provided herein are methods for using compositions that include a fusion protein having a YscF protein domain, a mature F1 protein domain, and a LcrV protein domain. In one embodiment the composition is used to confer immunity to plague, such as pneumonic plague, caused by Yersinia pestis. In one embodiment, the composition is administered to a mucosal surface, such as by an intranasal route. In one embodiment, the administration to a mucosal surface includes a vector that has a polynucleotide encoding a fusion protein, where the fusion protein includes a YscF protein domain, a mature F1 protein domain, and a LcrV protein domain. The administration is followed by a second administration by a different route, such as an intramuscular route. The second administration includes a fusion protein having the same three domains, and in one embodiment the fusion protein is the same one administered to a mucosal surface.
    Type: Grant
    Filed: September 17, 2020
    Date of Patent: May 2, 2023
    Assignees: The Board of Regents of the University of Texas System, Westport Bio, LLC
    Inventors: Ashok K. Chopra, Vladimir L. Motin, Eric Rothe